<DOC>
	<DOCNO>NCT02002065</DOCNO>
	<brief_summary>The purpose follow-up study evaluate five-year immune persistence one injection inactivate attenuate alive hepatitis A vaccine healthy child .</brief_summary>
	<brief_title>The Fifth-year Follow-up Study Phase IV Clinical Trial Hepatitis A Vaccine Healthy Children</brief_title>
	<detailed_description>In previous double-blind , randomize , phase IV clinical trial 2008 , 300 healthy Chinese child age 18 35 month old administer one dose inactivate attenuated alive hepatitis A vaccine . Series serum sample take immunogenicity immune persistence evaluation . Safety observation perform vaccination . This trial also approve Tianjin CDC Biomedical Ethics Committee 2008 . This study fifth-year follow-up research previous clinical trial .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject receive inactivated attenuate alive HAV vaccine previous trial Subjects refuse continue followup study</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hepatitis A</keyword>
	<keyword>inactivate hepatitis A vaccine</keyword>
	<keyword>attenuate alive hepatitis A vaccine</keyword>
	<keyword>immune persistence</keyword>
</DOC>